CSPC Pharma Signs $118.5 Million Deal for Two Molecules from University of Texas

CSPC Pharmaceutical of Hong Kong acquired global rights to two pre-clinical drug candidates developed by researchers at University of Texas institutions. The company paid $4.5 million upfront and could pay as much as $114 million in milestones for the rights. A CSPC subsidiary, AlaMab Therapeutics, will be responsible for developing the mAb candidates, which are derived from proteins called connexins and play a role in neuronal and skeletal tissue disease. AlaMab will work to gain approvals of the molecules in the US and China. More details... Stock Symbol: (HK: 1093) Share this with colleagues: // //